Plain Language Summaries is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • How to
  • FAQs
  • Publications
  • Advisory Panel
    • Plain Language Advisors
    • Scientific Content Advisors
  • Supporters
  • Blog
  • About us
  • Contact Us

daratumumab

28th Oct 2025

CEPHEUS study: daratumumab combination therapy for newly diagnosed multiple myeloma: plain language summary

8th Nov 2024

Final analysis of the GRIFFIN study: Daratumumab with lenalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma

24th Sep 2024

Plain language summary of the PERSEUS study on daratumumab combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma

This is a summary of a clinical trial called MAIA. The trial tested 2 combinations of cancer drugs (daratumumab plus lenalidomide and dexamethasone compared with lenalidomide and dexamethasone) in people with newly diagnosed multiple myeloma. None of the participants who took part in the study had been treated before or were eligible to receive stem-cell transplants
23rd May 2023

Plain Language Summary: the MAIA study, daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma

Copyright © 2026 · Plain Language Summaries · Terms and conditions · Privacy policy · Cookie policy